Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use.
OBJECTIVE
To evaluate the efficacy of celecoxib and placebo for controlling irregular uterine bleeding in Jadelle users.


METHODS
Randomized double blind placebo controlled trial.


METHODS
Family Planning Clinic, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.


METHODS
Forty Jadelle users with irregular bleeding were randomly allocated into two groups. Twenty users received celecoxib 200 mg once a day for five days and the other twenty users received the placebo in the same manner The participants were requested to maintain their daily record of bleeding, adverse effects, and satisfaction.


RESULTS
The percentage of the subjects whom bleeding was stopped within 7 days after initial treatment was significantly higher in the celecoxib group than in the placebo group (70% vs. 0%; p < 0.001). The mean duration of bleeding-free interval was significantly longer in celecoxib than placebo group (24.0 +/- 1.65 days vs. 10.0 +/- 6.50 days; p < 0.001). The mean duration of bleeding days was significantly shorter in celecoxib than placebo group (5.0 +/- 1.65 vs. 19.0 +/- 6.50 days; p < 0.001). Patients satisfaction in celecoxib group was significantly higher than the placebo group (80% vs. 30%; p < 0.001). There was no detectable adverse effect in both groups.


CONCLUSIONS
Celecoxib was more effective than placebo in the short-term control of irregular bleeding in Jadelle users. The mechanism of nonsteroidal anti-inflammatory drugs (NSAIDs) for the reduction of endometrial bleeding is likely from COX-2 inhibition.
Buasang
Kritsana
K
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Taneepanichskul
Surasak
S
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D000068579:Celecoxib; D003271:Contraceptive Agents, Female / Q000009:adverse effects; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004343:Drug Implants / Q000009:adverse effects*; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000009:adverse effects*; D008875:Middle Aged; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D013785:Thailand; D014592:Uterine Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D055815:Young Adult
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003271:Contraceptive Agents, Female; D052246:Cyclooxygenase 2 Inhibitors; D004343:Drug Implants; D011720:Pyrazoles; D013449:Sulfonamides; D016912:Levonorgestrel; D000068579:Celecoxib